SHMLF (SHL Telemedicine) Research & Development: $4.68 Mil (TTM As of Dec. 2025)


SHMLF SHL Telemedicine Ltd SHMLF
51 GF Score
Price $4.84
GF Value $13.95
! 3 Warning Signs
View Full Analysis

What is SHL Telemedicine Research & Development?

SHL Telemedicine SHMLF 51 Research & Development is $4.68 Mil as of Dec. 2025. GuruFocus rates SHMLF with a GF Score™ of 51/100 and a GF Value™ of $13.95. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. SHL Telemedicine's Research & Development for the six months ended in Dec. 2025 was $2.36 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $4.68 Mil.

SHL Telemedicine  (OTCPK:SHMLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

SHL Telemedicine Research & Development Related Terms

SHL Telemedicine Research & Development Historical Data

* Premium members only.

The historical data trend for SHL Telemedicine's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SHL Telemedicine Research & Development Chart

SHL Telemedicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.99 3.79 5.26 5.36 4.68

SHL Telemedicine Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 2.60 2.76 2.33 2.36
SHMLF
51GF Score
SHL Telemedicine Ltd SHMLF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SHL Telemedicine Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $4.68 Mil mean?
SHL Telemedicine (SHMLF) has a Research & Development of $4.68 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on SHL Telemedicine and its competitors.
Is SHL Telemedicine's Research & Development too high?
SHL Telemedicine's current Research & Development is $4.68 Mil. Overall, SHL Telemedicine has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Research & Development compare to VEEV and BTSG?
SHL Telemedicine's Research & Development of $4.68 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on SHL Telemedicine and its competitors. SHL Telemedicine's current Research & Development is $4.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current Research & Development of $4.68 Mil. The stock's GF Value™ is $13.95, compared to a current price of $4.84 — trading 65.3% below its estimated fair value. The current Research & Development is $4.68 Mil. SHL Telemedicine's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current Research & Development is $4.68 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SHL Telemedicine (SHMLF) Overvalued in 2026?

Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued. The current stock price of $4.84 is trading 65.3% below its estimated GF Value™ of $13.95.

Key valuation signals for SHMLF:

  • Research & Development: $4.68 Mil
  • GF Value™: $13.95 vs. price of $4.84 (65.3% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SHL Telemedicine Business Description

Other Exchanges 0QMX:UKSHLTN:Switzerland
Address 90 Yigal Alon Street, Tel Aviv, ISR, 67891
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
51GF Score

Get the complete analysis for SHMLF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.84
Price
$13.95
GF Value